[go: up one dir, main page]

MX2017004275A - Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. - Google Patents

Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.

Info

Publication number
MX2017004275A
MX2017004275A MX2017004275A MX2017004275A MX2017004275A MX 2017004275 A MX2017004275 A MX 2017004275A MX 2017004275 A MX2017004275 A MX 2017004275A MX 2017004275 A MX2017004275 A MX 2017004275A MX 2017004275 A MX2017004275 A MX 2017004275A
Authority
MX
Mexico
Prior art keywords
hiv
vaccine
antigen
episensus
subject
Prior art date
Application number
MX2017004275A
Other languages
English (en)
Other versions
MX391149B (es
Inventor
PICKER Louis
Frueh Klaus
Bruening Eric
T M Korber Bette
Theiler James
Marshall Emily
Original Assignee
Los Alamos Nat Security Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Alamos Nat Security Llc filed Critical Los Alamos Nat Security Llc
Publication of MX2017004275A publication Critical patent/MX2017004275A/es
Publication of MX391149B publication Critical patent/MX391149B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en la presente vacunas contra el VIH-1 que comprenden un portador y un antígeno episensus de población determinado usando el procedimiento EpiGraph. También se proporcionan vacunas contra el VIH-1 que comprenden un portador, un antígeno episensus de población, y un antígeno personalizado. También se proporcionan métodos para diseñar y producir una vacuna contra el VIH-1 para un sujeto que comprende diseñar antígenos de vacuna para cubrir óptimamente la diversidad dentro de un área geográfica usando una secuencia de aminoácidos de antígeno generada usando el procedimiento EpiGraph, y producir el antígeno de vacuna diseñado. También se proporciona el método para inducir una respuesta de células T de memoria efectoras que comprenden el diseño de la una o más secuencias de aminoácidos EpiGraph, producir una vacuna que comprende la una o más secuencias de aminoácidos EpiGraph y un vector, y administrar la vacuna a un sujeto. Se proporcionan además métodos para tratar VIH-1 en un sujeto que comprende administrar una cantidad efectiva de las vacunas contra el VIH-1 descritas al sujeto en necesidad de la misma.
MX2017004275A 2014-10-03 2015-10-05 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. MX391149B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462059497P 2014-10-03 2014-10-03
US201462059506P 2014-10-03 2014-10-03
PCT/US2015/054067 WO2016054654A1 (en) 2014-10-03 2015-10-05 Hiv vaccines comprising one or more population episensus antigens

Publications (2)

Publication Number Publication Date
MX2017004275A true MX2017004275A (es) 2018-01-17
MX391149B MX391149B (es) 2025-03-21

Family

ID=55631703

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017004275A MX391149B (es) 2014-10-03 2015-10-05 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
MX2022003663A MX2022003663A (es) 2014-10-03 2017-03-31 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
MX2022003664A MX2022003664A (es) 2014-10-03 2017-03-31 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022003663A MX2022003663A (es) 2014-10-03 2017-03-31 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
MX2022003664A MX2022003664A (es) 2014-10-03 2017-03-31 Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.

Country Status (16)

Country Link
US (3) US10894078B2 (es)
EP (1) EP3200878B1 (es)
JP (3) JP2017531693A (es)
KR (1) KR102633096B1 (es)
CN (1) CN108064181A (es)
AU (2) AU2015327797A1 (es)
CA (1) CA2963573C (es)
EA (1) EA201790680A1 (es)
HK (1) HK1254806A1 (es)
IL (1) IL251469B2 (es)
MA (1) MA40783A (es)
MX (3) MX391149B (es)
SG (1) SG11201702729YA (es)
UA (1) UA126890C2 (es)
WO (1) WO2016054654A1 (es)
ZA (1) ZA202206809B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
IL300730A (en) * 2016-07-08 2023-04-01 American Gene Tech Int Inc Pre-HIV vaccine and immunotherapy
US20210317192A9 (en) * 2019-05-29 2021-10-14 Massachusetts Institute Of Technology Hiv-1 specific immunogen compositions and methods of use
CN120775062A (zh) 2019-07-16 2025-10-14 吉利德科学公司 Hiv疫苗及其制备和使用方法
CA3149415A1 (en) 2019-08-29 2021-03-11 Eric Bruening Hepatitis b virus vaccines
US12053517B2 (en) * 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using
CA3226699A1 (en) 2021-08-31 2023-03-09 Vir Biotechnology, Inc. Recombinant hcmv vectors and uses thereof
TW202436326A (zh) * 2023-02-13 2024-09-16 長怡 王 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者
CN116524994B (zh) * 2023-02-20 2026-01-30 中国科学院天津工业生物技术研究所 一种基于贪婪算法的菌株构建排程设计方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
AUPR842501A0 (en) * 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20070054262A1 (en) * 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
AU2011203095A1 (en) 2003-09-17 2011-07-21 Duke University Consensus/Ancestral Immunogens
AU2004274937B9 (en) 2003-09-17 2011-04-14 Duke University Consensus/ancestral immunogens
MXPA06003977A (es) 2003-10-10 2006-06-27 Powderject Vaccines Inc Metodo.
CA2837748C (en) 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
CN101969996A (zh) * 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
JP2009544333A (ja) * 2006-07-28 2009-12-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改良されたワクチンおよびそれを使用するための方法
US20110123485A1 (en) * 2007-03-27 2011-05-26 President And Fellows Of Harvard College Viral vectors for delivering vaccines for hiv and other infectious diseases
US20100183651A1 (en) 2007-03-30 2010-07-22 Finnefrock Adam C Broadly Representative Antigen Sequences and Method for Selection
BR122021004758B1 (pt) * 2008-11-18 2022-04-19 Los Alamos National Security, Llc Uso de um peptídeo viral otimizado, vacina e seu método de fabricação, vetor e kit
KR20120093941A (ko) * 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
SI3351636T1 (sl) 2010-05-14 2020-11-30 Oregon Health & Science Universitiy Rekombinantni HCMV in RHCMV vektorji, ki kodirajo heterologni antigen izoliran iz paramyxoviridae virusa njihove uporabe
US8557787B2 (en) * 2011-05-13 2013-10-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9415099B2 (en) 2012-03-02 2016-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of altering the immundominance hierarchy of HIV gag by DNA vaccine expressing conserved regions
HK1214509A1 (zh) * 2013-01-07 2016-07-29 Beth Israel Deaconess Medical Center, Inc. 穏定的人類免疫缺陷病毒(hiv)包膜蛋白基因(env)三聚體疫苗及其使用方法
AU2014225886B2 (en) 2013-03-05 2020-04-16 Oregon Health & Science University Cytomegalovirus vectors enabling control of T cell targeting
WO2015128421A1 (en) 2014-02-28 2015-09-03 Crucell Holland B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
KR102403547B1 (ko) 2014-07-16 2022-05-30 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
CN112121160A (zh) 2014-09-26 2020-12-25 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EA038974B1 (ru) 2015-12-15 2021-11-17 Янссен Вэксинс Энд Превеншн Б.В. Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения

Also Published As

Publication number Publication date
AU2015327797A1 (en) 2017-05-11
MX2022003663A (es) 2022-04-25
CA2963573A1 (en) 2016-04-07
IL251469B1 (en) 2023-01-01
JP2017531693A (ja) 2017-10-26
US11628215B2 (en) 2023-04-18
HK1254806A1 (zh) 2019-07-26
JP7441340B2 (ja) 2024-03-06
EA201790680A1 (ru) 2017-11-30
MX391149B (es) 2025-03-21
NZ731173A (en) 2024-04-26
SG11201702729YA (en) 2017-04-27
US20170319679A1 (en) 2017-11-09
CN108064181A (zh) 2018-05-22
JP2021035946A (ja) 2021-03-04
AU2021218141A1 (en) 2021-09-09
US11554168B2 (en) 2023-01-17
EP3200878A4 (en) 2018-05-30
EP3200878A1 (en) 2017-08-09
US20210046175A1 (en) 2021-02-18
US10894078B2 (en) 2021-01-19
WO2016054654A1 (en) 2016-04-07
MX2022003664A (es) 2022-04-25
EP3200878B1 (en) 2025-06-04
KR102633096B1 (ko) 2024-02-02
JP7212020B2 (ja) 2023-01-24
CA2963573C (en) 2024-02-06
IL251469B2 (en) 2023-05-01
US20210046174A1 (en) 2021-02-18
JP2023059272A (ja) 2023-04-26
KR20170122711A (ko) 2017-11-06
UA126890C2 (uk) 2023-02-22
ZA202206809B (en) 2023-11-29
IL251469A0 (en) 2017-05-29
AU2021218141B2 (en) 2024-06-06
MA40783A (fr) 2017-08-08
BR112017006865A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
MX2017004275A (es) Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
CY1124867T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
CY1124254T1 (el) Μεθοδοι και συνθεσεις για την προκληση προστατευτικης ανοσιας εναντι λοιμωξης ιου της ανθρωπινης ανοσοανεπαρκειας
CY1123563T1 (el) Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
UY36458A (es) Anticuerpos humanos para hemaglutinina influenza.
EA201891415A8 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
MX370191B (es) Composiciones y su uso en el tratamiento de la inmunodeficiencia.
MX2016011537A (es) Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras.
MX384422B (es) Vector que expresa conjuntamente vacunas y moléculas coestimuladoras
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MX2017000169A (es) Un poliepitope quimerico de virus de dengue compuesto por fragmentos de proteinas no estructurales y su uso en una composicion inmunogenica contra infeccion de virus de dengue.
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
MX381211B (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
PE20151588A1 (es) Vacuna contra el virus del dengue
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
EA201690115A1 (ru) Комбинированные иммуногенные композиции
CL2019000705A1 (es) Nuevos promotores.
MX2019006244A (es) Construcciones de vectores virales para la expresion de adyuvantes geneticos que activan la ruta sting.
BR112018005728A2 (pt) epítopos de célula t de reatividade cruzada de hiv, siv e fiv para vacinas em humanos e gatos
AR117942A1 (es) Vacunas contra el zika, composiciones inmunogénicas y métodos que las utilizan
EA202191862A2 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения